China Fertility Services Market Research Report By Underlying Cause (Male Infertility, Female Infertility) and By Treatment Type (ART, Infertility Drugs)-Forecast to 2035

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

1.1. Market Overview

1.2. Key Findings

1.3. Market Segmentation

1.4. Competitive Landscape

1.5. Challenges and Opportunities

1.6. Future Outlook

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the study

2.2.1. Research Objective

2.2.2. Assumption

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value chain Analysis

5.2. Porter's Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. CHINA FERTILITY SERVICES MARKET, BY UNDERLYING CAUSE (USD BILLION)

6.1. Male Infertility

6.2. Female Infertility

7. CHINA FERTILITY SERVICES MARKET, BY TREATMENT TYPE (USD BILLION)

7.1. ART

7.2. Infertility Drugs

8. COMPETITIVE LANDSCAPE

8.1. Overview

8.2. Competitive Analysis

8.3. Market share Analysis

8.4. Major Growth Strategy in the Fertility Services Market

8.5. Competitive Benchmarking

8.6. Leading Players in Terms of Number of Developments in the Fertility Services Market

8.7. Key developments and growth strategies

8.7.1. New Product Launch/Service Deployment

8.7.2. Merger & Acquisitions

8.7.3. Joint Ventures

8.8. Major Players Financial Matrix

8.8.1. Sales and Operating Income

8.8.2. Major Players R&D Expenditure. 2023

9. COMPANY PROFILES

9.1. Reproductive Health Institute of Shanghai

9.1.1. Financial Overview

9.1.2. Products Offered

9.1.3. Key Developments

9.1.4. SWOT Analysis

9.1.5. Key Strategies

9.2. Peking University Third Hospital

9.2.1. Financial Overview

9.2.2. Products Offered

9.2.3. Key Developments

9.2.4. SWOT Analysis

9.2.5. Key Strategies

9.3. Soochow University

9.3.1. Financial Overview

9.3.2. Products Offered

9.3.3. Key Developments

9.3.4. SWOT Analysis

9.3.5. Key Strategies

9.4. Bohua Zhihe

9.4.1. Financial Overview

9.4.2. Products Offered

9.4.3. Key Developments

9.4.4. SWOT Analysis

9.4.5. Key Strategies

9.5. Reproductive Medicine Center of Guangdong

9.5.1. Financial Overview

9.5.2. Products Offered

9.5.3. Key Developments

9.5.4. SWOT Analysis

9.5.5. Key Strategies

9.6. BGI Genomics

9.6.1. Financial Overview

9.6.2. Products Offered

9.6.3. Key Developments

9.6.4. SWOT Analysis

9.6.5. Key Strategies

9.7. Wuzhou Fuhua Hospital

9.7.1. Financial Overview

9.7.2. Products Offered

9.7.3. Key Developments

9.7.4. SWOT Analysis

9.7.5. Key Strategies

9.8. Nanjing Medical University

9.8.1. Financial Overview

9.8.2. Products Offered

9.8.3. Key Developments

9.8.4. SWOT Analysis

9.8.5. Key Strategies

9.9. Tianjin Medical University

9.9.1. Financial Overview

9.9.2. Products Offered

9.9.3. Key Developments

9.9.4. SWOT Analysis

9.9.5. Key Strategies

9.10. IVF Spain

9.10.1. Financial Overview

9.10.2. Products Offered

9.10.3. Key Developments

9.10.4. SWOT Analysis

9.10.5. Key Strategies

9.11. FuGen Group

9.11.1. Financial Overview

9.11.2. Products Offered

9.11.3. Key Developments

9.11.4. SWOT Analysis

9.11.5. Key Strategies

9.12. Chinese Academy of Sciences

9.12.1. Financial Overview

9.12.2. Products Offered

9.12.3. Key Developments

9.12.4. SWOT Analysis

9.12.5. Key Strategies

9.13. Zheng Kang Yi

9.13.1. Financial Overview

9.13.2. Products Offered

9.13.3. Key Developments

9.13.4. SWOT Analysis

9.13.5. Key Strategies

9.14. New Hope Fertility

9.14.1. Financial Overview

9.14.2. Products Offered

9.14.3. Key Developments

9.14.4. SWOT Analysis

9.14.5. Key Strategies

9.15. Beijing Shijitan Hospital

9.15.1. Financial Overview

9.15.2. Products Offered

9.15.3. Key Developments

9.15.4. SWOT Analysis

9.15.5. Key Strategies

10. APPENDIX

10.1. References

10.2. Related Reports

LIST OF TABLES

TABLE 1. LIST OF ASSUMPTIONS

TABLE 2. CHINA FERTILITY SERVICES MARKET SIZE ESTIMATES & FORECAST, BY UNDERLYING CAUSE, 2019-2035 (USD BILLIONS)

TABLE 3. CHINA FERTILITY SERVICES MARKET SIZE ESTIMATES & FORECAST, BY TREATMENT TYPE, 2019-2035 (USD BILLIONS)

TABLE 4. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL

TABLE 5. ACQUISITION/PARTNERSHIP

LIST OF FIGURES

FIGURE 1. MARKET SYNOPSIS

FIGURE 2. CHINA FERTILITY SERVICES MARKET ANALYSIS BY UNDERLYING CAUSE

FIGURE 3. CHINA FERTILITY SERVICES MARKET ANALYSIS BY TREATMENT TYPE

FIGURE 4. KEY BUYING CRITERIA OF FERTILITY SERVICES MARKET

FIGURE 5. RESEARCH PROCESS OF MRFR

FIGURE 6. DRO ANALYSIS OF FERTILITY SERVICES MARKET

FIGURE 7. DRIVERS IMPACT ANALYSIS: FERTILITY SERVICES MARKET

FIGURE 8. RESTRAINTS IMPACT ANALYSIS: FERTILITY SERVICES MARKET

FIGURE 9. SUPPLY / VALUE CHAIN: FERTILITY SERVICES MARKET

FIGURE 10. FERTILITY SERVICES MARKET, BY UNDERLYING CAUSE, 2024 (% SHARE)

FIGURE 11. FERTILITY SERVICES MARKET, BY UNDERLYING CAUSE, 2019 TO 2035 (USD Billions)

FIGURE 12. FERTILITY SERVICES MARKET, BY TREATMENT TYPE, 2024 (% SHARE)

FIGURE 13. FERTILITY SERVICES MARKET, BY TREATMENT TYPE, 2019 TO 2035 (USD Billions)

FIGURE 14. BENCHMARKING OF MAJOR COMPETITORS